Insider Transactions in Q3 2024 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 03
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,050
-13.56%
|
$226,250
$25.28 P/Share
|
|
Sep 03
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,050
+12.43%
|
$45,250
$5.72 P/Share
|
|
Aug 26
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,870
-28.64%
|
$246,750
$25.01 P/Share
|
|
Aug 26
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,870
+13.44%
|
$49,350
$5.72 P/Share
|
|
Aug 26
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-39.21%
|
$500,000
$25.22 P/Share
|
|
Aug 01
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-9.6%
|
$120,960
$21.79 P/Share
|
|
Aug 01
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+15.95%
|
$5,760
$1.86 P/Share
|
|
Aug 01
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,477
-3.2%
|
$73,017
$21.83 P/Share
|
|
Jul 30
2024
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,490
-4.37%
|
$49,800
$20.67 P/Share
|
|
Jul 30
2024
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+5.04%
|
-
|
|
Jul 30
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,920
-10.61%
|
$58,400
$20.67 P/Share
|
|
Jul 30
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,674
+9.29%
|
-
|
|
Jul 30
2024
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,408
-7.02%
|
$68,160
$20.67 P/Share
|
|
Jul 30
2024
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,957
+6.14%
|
-
|
|
Jul 17
2024
|
Lori Anne Kunkel Director |
SELL
Bona fide gift
|
Direct |
54,027
-100.0%
|
-
|
|
Jul 01
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-11.63%
|
$120,960
$21.13 P/Share
|
|
Jul 01
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+18.37%
|
$5,760
$1.86 P/Share
|